Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, March 2000, p. 794-797, Vol. 44, No. 3
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Delavirdine Susceptibilities and Associated Reverse Transcriptase
Mutations in Human Immunodeficiency Virus Type 1 Isolates from
Patients in a Phase I/II Trial of Delavirdine Monotherapy
(ACTG 260)
L. M.
Demeter,1,*
R. W.
Shafer,2
P. M.
Meehan,3
J.
Holden-Wiltse,3
M. A.
Fischl,4
W. W.
Freimuth,5
M. F.
Para,6 and
R. C.
Reichman1
University of Rochester School of Medicine
and Dentistry, Rochester, New York1;
Stanford University, Palo Alto,
California2; Harvard School of Public
Health, Boston, Massachusetts3;
University of Miami, Miami, Florida4;
Pharmacia and Upjohn, Kalamazoo,
Michigan5; and Ohio State University,
Columbus, Ohio6
Received 23 August 1999/Returned for modification 4 November
1999/Accepted 29 November 1999
The development of human immunodeficiency virus type 1 resistance
to delavirdine (DLV) was studied in subjects receiving DLV monotherapy.
Phenotypic resistance developed in 28 of 30 subjects within 8 weeks.
K103N and Y181C, which confer nonnucleoside reverse transcriptase
inhibitor (NNRTI) cross-resistance, were the predominant reverse
transcriptase mutations. P236L, which confers DLV resistance but
hypersensitivity to other NNRTIs, developed in <10% of isolates.
*
Corresponding author. Mailing address: University of
Rochester Infectious Diseases Unit, 601 Elmwood Ave., Box 689, Rochester, NY 14642. Phone: (716) 275-4764. Fax: (716) 442-9328. E-mail: Lisa_Demeter{at}urmc.rochester.edu.
Antimicrobial Agents and Chemotherapy, March 2000, p. 794-797, Vol. 44, No. 3
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Herrera, C., Cranage, M., McGowan, I., Anton, P., Shattock, R. J.
(2009). Reverse Transcriptase Inhibitors as Potential Colorectal Microbicides. Antimicrob. Agents Chemother.
53: 1797-1807
[Abstract]
[Full Text]
-
Dykes, C., Demeter, L. M.
(2007). Clinical Significance of Human Immunodeficiency Virus Type 1 Replication Fitness. Clin. Microbiol. Rev.
20: 550-578
[Abstract]
[Full Text]
-
Joly, V., Descamps, D., Peytavin, G., Touati, F., Mentre, F., Duval, X., Delarue, S., Yeni, P., Brun-Vezinet, F.
(2004). Evolution of Human Immunodeficiency Virus Type 1 (HIV-1) Resistance Mutations in Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs) in HIV-1-Infected Patients Switched to Antiretroviral Therapy without NNRTIs. Antimicrob. Agents Chemother.
48: 172-175
[Abstract]
[Full Text]
-
Huang, W., Gamarnik, A., Limoli, K., Petropoulos, C. J., Whitcomb, J. M.
(2002). Amino Acid Substitutions at Position 190 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Increase Susceptibility to Delavirdine and Impair Virus Replication. J. Virol.
77: 1512-1523
[Abstract]
[Full Text]
-
Aslanzadeh, J.
(2002). HIV Resistance Testing: an Update. Annals of Clinical & Laboratory Science
32: 406-413
[Abstract]
[Full Text]
-
Harrigan, P. R., Salim, M., Stammers, D. K., Wynhoven, B., Brumme, Z. L., McKenna, P., Larder, B., Kemp, S. D.
(2002). A Mutation in the 3' Region of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase (Y318F) Associated with Nonnucleoside Reverse Transcriptase Inhibitor Resistance. J. Virol.
76: 6836-6840
[Abstract]
[Full Text]
-
Shafer, R. W.
(2002). Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance. Clin. Microbiol. Rev.
15: 247-277
[Abstract]
[Full Text]
-
Hermankova, M., Ray, S. C., Ruff, C., Powell-Davis, M., Ingersoll, R., D'Aquila, R. T., Quinn, T. C., Siliciano, J. D., Siliciano, R. F., Persaud, D.
(2001). HIV-1 Drug Resistance Profiles in Children and Adults With Viral Load of <50 Copies/mL Receiving Combination Therapy. JAMA
286: 196-207
[Abstract]
[Full Text]
-
Bacheler, L., Jeffrey, S., Hanna, G., D'Aquila, R., Wallace, L., Logue, K., Cordova, B., Hertogs, K., Larder, B., Buckery, R., Baker, D., Gallagher, K., Scarnati, H., Tritch, R., Rizzo, C.
(2001). Genotypic Correlates of Phenotypic Resistance to Efavirenz in Virus Isolates from Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor Therapy. J. Virol.
75: 4999-5008
[Abstract]
[Full Text]
-
Joly, V., Moroni, M., Concia, E., Lazzarin, A., Hirschel, B., Jost, J., Chiodo, F., Bentwich, Z., Love, W. C., Hawkins, D. A., Wilkins, E. G. L., Gatell, A. J., Vetter, N., Greenwald, C., Freimuth, W. W., de Cian, W., The M/3331/0013B Study Group,
(2000). Delavirdine in Combination with Zidovudine in Treatment of Human Immunodeficiency Virus Type 1-Infected Patients: Evaluation of Efficacy and Emergence of Viral Resistance in a Randomized, Comparative Phase III Trial. Antimicrob. Agents Chemother.
44: 3155-3157
[Abstract]
[Full Text]
-
Archer, R. H., Dykes, C., Gerondelis, P., Lloyd, A., Fay, P., Reichman, R. C., Bambara, R. A., Demeter, L. M.
(2000). Mutants of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Resistant to Nonnucleoside Reverse Transcriptase Inhibitors Demonstrate Altered Rates of RNase H Cleavage That Correlate with HIV-1 Replication Fitness in Cell Culture. J. Virol.
74: 8390-8401
[Abstract]
[Full Text]
-
Bacheler, L. T., Anton, E. D., Kudish, P., Baker, D., Bunville, J., Krakowski, K., Bolling, L., Aujay, M., Wang, X. V., Ellis, D., Becker, M. F., Lasut, A. L., George, H. J., Spalding, D. R., Hollis, G., Abremski, K.
(2000). Human Immunodeficiency Virus Type 1 Mutations Selected in Patients Failing Efavirenz Combination Therapy. Antimicrob. Agents Chemother.
44: 2475-2484
[Abstract]
[Full Text]
-
Hirsch, M. S., Brun-Vezinet, F., D'Aquila, R. T., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Loveday, C., Mellors, J. W., Clotet, B., Conway, B., Demeter, L. M., Vella, S., Jacobsen, D. M., Richman, D. D.
(2000). Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: Recommendations of an International AIDS Society-USA Panel. JAMA
283: 2417-2426
[Abstract]
[Full Text]